List view / Grid view
1 February 2018 | By PerkinElmer
This webinar discussed a screening assay that recapitulates the activation of ER stress sensor IRE1 and an assay to quantify cell migration phenotypes, as applied to cardiovascular target validation and drug discovery.
Scientists have rebuilt adenoviruses so that they effectively recognise and infect tumour cells.
A study has laid the groundwork for the use of PD-1 inhibitors with an aggressive form of brain cancer, namely supratentorial pediatric ependymoma.
Analysing individuals' genotypes and immunotypes could yield customised treatments for prostate cancer...
Johns Hopkins scientists have used a form of artificial intelligence to create a map that compares types of cellular receptors, the chemical ‘antennas’ on the surface of immune system T-cells.
4 January 2018 | By IntelliCyt Corporation
In this webinar, speakers discussed how the IntelliCyt iQue Screener Plus platform is being utilised to deliver rich datasets for compound screening, target validation and is how it is transforming immuno-oncology.
One of the biggest challenges facing drug discovery across all therapeutic modalities (small molecule, biologics, and cellular) remains the balance between physiological relevance and throughput.
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.1
Scientists have discovered a compound that causes cancer cells to self-destruct while sparing healthy cells...
27 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the challenges faced with antibody screening and how the iQue Screener can give an evaluation of cell killing mechanism, screening for immune checkpoint inhibitors and more...
22 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the need for robust high content tools for current immunotherapeutic approaches, and how IntelliCyt's iQue Screener PLUS can give functional efficacy of immuno-oncology therapies...
A novel chemical dubbed "T-REX," along with a patent-pending targeting molecule have uncovered interesting facets of several well-known cancer-cell mutations that, if present in a patient, could inform treatment options and potentially produce more favourable outcomes...
AstraZeneca and MedImmune, have today announced that the US Food and Drug Administration has granted breakthrough therapy designation for Imfinzi for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer...
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer...
Researchers have developed a new tools to increase immune response against cancer and infections...
